Matrine Vs Niacinamide: Which Is Better For Cosmetic?

Niacinamide (Vitamin B3) is a mature, highly versatile synthetic cosmetic active with decades of standardized safety verification and global clinical trial data support. Its core efficacy logic is centered on skin barrier regulation and oil balance adjustment: it inhibits sebaceous gland lipid transport to reduce excessive sebum secretion, blocks melanosome transfer to fade post-inflammatory acne pigmentation, and upregulates ceramide synthesis to repair fragile skin barriers. Notably, Niacinamide has no direct bactericidal or bacteriostatic effect on acne-causing bacteria, and cannot rapidly intervene in acute acne inflammation. With ultra-wide formula compatibility, odorless and color-stable characteristics, and a fully mature global supply chain, it has become a universal staple ingredient in European pharmacy daily skincare and North American mass-market oil-control products.

In practical formula verification, Niacinamide cannot inhibit the activity of acne pathogenic bacteria, and has no obvious improvement effect on severe pustular inflammatory acne, so it cannot replace Matrine in professional anti-acne repair.

Niacinamide focuses on long-term oil control and post-acne repair, with no acute anti-acne efficacy. Clinical data shows that continuous use of 2–4% Niacinamide for 12 weeks can reduce facial sebum production by 20–27%, refine rough pore texture, and fade post-inflammatory pigmentation by about 22%. By strengthening skin barrier integrity, it reduces recurrent acne caused by fragile skin and oily imbalance. In practical formula verification, Niacinamide cannot inhibit the activity of acne pathogenic bacteria, and has no obvious improvement effect on severe pustular inflammatory acne, so it cannot replace Matrine in professional anti-acne repair formulas.

Niacinamide boasts excellent formula stability and low production risk, which is the core reason for its wide popularity in Western mass production. It maintains stable chemical properties in the pH range of 4.0–7.0, adapting to most acidic, neutral and weakly alkaline cosmetic systems. After 90-day 45°C high-temperature accelerated aging and room-temperature light storage tests, the active retention rate of Niacinamide finished products remains above 92%, with no discoloration, precipitation or odor deterioration. The raw material is pure white odorless powder, compatible with transparent PET ordinary packaging, and has extremely low batch fluctuation. The only key procurement quality control index is nicotinic acid impurity content; excessive impurities (exceeding 50ppm) will cause transient flushing and stinging on sensitive skin.

Matrine has prominent stability and sensory defects in formula application. As a plant alkaloid, its stable pH window is limited to 5.5–7.2; when the system pH is lower than 5.5, Matrine is prone to salt precipitation, resulting in formula turbidity and activity attenuation. Light stability test data shows that unencapsulated Matrine loses 38% of its biological activity after 60 days of continuous light exposure, and the aqueous formula gradually turns yellow-brown, seriously affecting the appearance of high-transparency skincare products. In addition, Matrine has a unique persistent bitter taste, which cannot be completely covered by conventional flavors, requiring special taste-masking excipients. In mass production, finished products must use amber opaque packaging to avoid photodegradation, which increases packaging and formula adjustment costs.

Niacinamide is one of the most versatile actives for combining with retinol, glycolic acid and salicylic acid. When paired with low to medium strength exfoliants, it reduces barrier irritation by reinforcing ceramide synthesis, a well-established combination widely used in Western pharmacy acne essences.

Matrine's acid compatibility is poor, with strict formula restrictions. It can be stably compounded with low-dose salicylic acid and LHA to achieve synergistic anti-acne effects, but it is extremely sensitive to strong acidic environments. Test data verifies that when the formula pH is lower than 5.0, Matrine's antibacterial activity drops by 45%, and the risk of molecular structural dissociation increases significantly. High-concentration AHAs compounded with Matrine will superimpose skin irritation, increasing the probability of sensitive skin redness and stinging by 28%. Therefore, Matrine is not suitable for one-bottle multi-effect strong acid exfoliation formulas popular in Western markets, and must pass strict human patch testing before mass production.

Niacinamide has complete SCCS and CIR safety assessments. PIF documentation is readily available for EU cosmetic filing under EC 1223/2009, with no special additional toxicology requirements. It is accepted across pharmacy, clean beauty and mass-market segments in both EU and US markets.

Matrine faces obvious regulatory and filing barriers in European and American markets. At present, most cosmetic-grade high-purity Matrine relies on imported raw materials from Asia, and there is a lack of independent GLP-standard toxicology test data recognized by EU and US regulatory agencies. Local European brands need to supplement complete skin irritation, acute toxicity, impurity safety evaluation and other documents to complete PIF filing, which extends the filing cycle by 2–3 months and increases additional compliance costs. Meanwhile, Western clean beauty certification institutions have strict review standards for plant alkaloid ingredients, and explicitly prohibit exaggerated antibacterial and therapeutic claims. Cosmetic-grade Matrine cannot be promoted as a medicinal anti-acne ingredient, resulting in limited marketing space compared with mature ingredients.

Niacinamide has a global, mature supply base with abundant spot inventory. MOQs are low, and raw material pricing is highly competitive, ideal for mass-market large batch production. Quality control mainly focuses on nicotinic acid impurity limits.

High-purity cosmetic-grade Matrine has a higher market price and higher MOQ threshold than Niacinamide, with obvious supply chain barriers for small-batch DTC brands. The market is flooded with low-cost crude Matrine products, which generally have problems such as insufficient HPLC purity, unqualified alkaloid impurity content and unstable batch activity, leading to 15–20% efficacy fluctuation in finished products. Professional European procurement teams will prioritize verifying supplier COA reports, focusing on detecting effective ingredient content and impurity spectrum to ensure batch consistency, which further increases the procurement threshold of Matrine.

Niacinamide enjoys strong consumer recognition across EU pharmacy and US DTC channels. Shoppers are familiar with its benefits for oil control, pores and post-acne marks, making it a low-risk ingredient for product storytelling.

Matrine is still a niche emerging ingredient in Western terminal markets, with low consumer awareness. Its plant-derived attribute can cater to partial clean beauty positioning, but brands need to invest a lot of resources in popular science education. Restricted by EU advertising regulations, it cannot promote strong antibacterial and therapeutic effects, resulting in weak terminal market conversion power. It is mostly used in professional line medical beauty repair and targeted anti-acne niche products, and cannot form universal consumer cognition like Niacinamide.

At standard 2–4% loading, niacinamide has a favorable safety profile for sensitive acne skin; only a small subset of users reports temporary flushing caused by nicotinic acid impurities.

Matrine has a narrow safe use window with higher skin irritation risk. Human skin patch tests show that when the dosage reaches 0.3% and above, 18% of sensitive acne skin subjects have varying degrees of stinging, burning and flushing reactions. Its irritation risk increases linearly with dosage, and it is not suitable for high-concentration addition. In contrast, Niacinamide has mild and stable skin affinity, and the 2–4% conventional dosage is friendly to most sensitive skin, only a small number of users have temporary flushing caused by excessive nicotinic acid impurities, with extremely low adverse reaction rate.

Niacinamide's white powder form, neutral odor and color stability grant packaging flexibility; clear PET bottles are acceptable for essences and lotions.

Matrine's raw material is pale yellow crystalline powder with inherent bitter taste, which is easy to remain in finished products and affect the sensory experience. It is sensitive to light and heat, and long-term storage will cause formula yellowing and activity decline, so finished products can only use amber or opaque light-proof packaging, which limits product appearance design. Formulators also need to add special taste-masking agents and stabilizers, increasing formula complexity and overall production costs.

• Priority to select Matrine: Formulas targeting active inflammatory pustular acne, plant-based dermocosmetic acne serums, scalp products for inflammatory itching and bacterial imbalance.
• Priority to select Niacinamide: Mass-market oil control, post-acne PIH fading, daily barrier maintenance, multi-active blends with retinol or AHAs, and low-cost pharmacy skincare lines.
• Dual-active compound strategy: Many European brands combine Matrine and Niacinamide for all-round acne care: Matrine addresses active inflammation and bacteria, Niacinamide regulates sebum and fades pigmentation. Recommended addition range: Matrine 0.1–0.3%, Niacinamide 2–4%.
• Potential compound risks: The compound system of Matrine and Niacinamide has strict pH restrictions. When the pH is lower than 5.5, Matrine precipitation risk increases by 32%, which will cause formula turbidity and activity attenuation. High-dose simultaneous addition of the two ingredients will superimpose skin burden, increasing the irritation probability of hypersensitive acne skin by 21%. In actual mass production, the system pH must be stably controlled at 5.5–6.5, and finished products need to complete 90-day accelerated stability test and human patch verification to avoid shelf-life quality problems and user adverse reactions.

If you want know more details of Niacinamide powder and Matrine powder, be free contact product link to know.

Also send mail to us : haozebio2014@gmail.com

[1] Journal of Cosmetic Dermatology. Anti-inflammatory and Antibacterial Activity of Matrine on Acne-affected Skin, 2024

[2] EU SCCS. Scientific Opinion on Niacinamide Used in Cosmetic Products, 2023

[3] CosIng & CIR Database: Safety Profile of Matrine in Topical Applications, 2025

[4] International Journal of Cosmetic Science. Sebum-Regulating Efficacy of Topical Niacinamide, 2024

[5] European Dermocosmetic Market Report: Anti-Acne Active Ingredient Trends 2024–2026

[6] Formulation Journal. Stability Evaluation of Alkaloid Actives in Cosmetic Emulsions, 2025